References:
1. Negrin RS. Introduction to the review series on “Advances in
hematopoietic cell transplantation”. Am Soc Hematology; 2014.
2. Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD.
British journal of haematology. 2013;160(3):288-302.
3. Qian L, Wu Z, Shen J. Advances in the treatment of acute
graft‐versus‐host disease. Journal of cellular and molecular medicine.
2013;17(8):966-75.
4. Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, et al.
Immunomodulation effects of mesenchymal stromal cells on acute
graft-versus-host disease after hematopoietic stem cell transplantation.
Biology of Blood and Marrow Transplantation. 2015;21(1):97-104.
5. Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von
Bergwelt-Baildon M, Held SA, et al. Novel treatment concepts for
graft-versus-host disease. Blood, The Journal of the American Society of
Hematology. 2012;119(1):16-25.
6. Lim J-Y, Park M-J, Im K-I, Kim N, Jeon E-J, Kim E-J, et al.
Combination cell therapy using mesenchymal stem cells and regulatory
T-cells provides a synergistic immunomodulatory effect associated with
reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute
graft-versus-host disease model. Cell transplantation.
2014;23(6):703-14.
7. Bernardo M, Ball L, Cometa A, Roelofs H, Zecca M, Avanzini M, et al.
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening
acute GVHD, but does not reduce the risk of graft failure in pediatric
patients undergoing allogeneic umbilical cord blood transplantation.
Bone marrow transplantation. 2011;46(2):200.
8. Di Ianni M, Del Papa B, De Ioanni M, Moretti L, Bonifacio E, Cecchini
D, et al. Mesenchymal cells recruit and regulate T regulatory cells.
Experimental hematology. 2008;36(3):309-18.
9. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a
billion or so and call me in the morning. Immunity. 2009;30(5):656-65.
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood. 2005;105(4):1815-22.
11. Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Correction:
mesenchymal stem cells inhibit human th17 cell differentiation and
function and induce a T regulatory cell phenotype. The Journal of
Immunology. 2013;191(11):5777-.
12. Stenger EO, Krishnamurti L, Galipeau J. Mesenchymal stromal cells to
modulate immune reconstitution early post-hematopoietic cell
transplantation. BMC immunology. 2015;16(1):74.
13. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A,
et al. Treatment of severe steroid resistant acute GVHD with mesenchymal
stromal cells (MSC). American journal of blood research. 2013;3(3):225.
14. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi
A, et al. Treatment of graft versus host disease with mesenchymal
stromal cells: a phase I study on 40 adult and pediatric patients.
Biology of blood and marrow transplantation. 2014;20(3):375-81.
15. Berger M, Signorino E, Muraro M, Quarello P, Biasin E, Nesi F, et
al. Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 following
HSCT and their role as GVHD biomarkers in paediatric patients. Bone
marrow transplantation. 2013;48(9):1230.
16. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom R. Soluble
interleukin-2 receptor level as an indicator of liver allograft
rejection. Transplantation. 1989;47(1):77-81.
17. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T,
et al. Regenerating islet-derived 3-alpha is a biomarker of
gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-8.
18. Lee SH, Lee M, Yoo K, Kim D, Son M, Sung K, et al.
Co-transplantation of third-party umbilical cord blood-derived MSCs
promotes engraftment in children undergoing unrelated umbilical cord
blood transplantation. Bone marrow transplantation. 2013;48(8):1040-5.
19. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, et al.
Change in plasma tumor necrosis factor receptor 1 levels in the first
week after myeloablative allogeneic transplantation correlates with
severity and incidence of GVHD and survival. Blood. 2008;112(4):1539-42.
20. August K, Chiang K, Bostick R, Flanders W, Waller E, Langston A, et
al. Biomarkers of immune activation to screen for severe, acute GVHD.
Bone marrow transplantation. 2011;46(4):601.
21. Marafini I, Di Sabatino A, Zorzi F, Monteleone I, Sedda S, Cupi M,
et al. Serum regenerating islet‐derived 3‐alpha is a biomarker of
mucosal enteropathies. Alimentary pharmacology & therapeutics.
2014;40(8):974-81.
22. Ito S, Barrett AJ. ST2: the biomarker at the heart of GVHD severity.
Blood. 2015;125(1):10-1.
23. Kanaya M, Shibuya K, Hirochika R, Kanemoto M, Ohashi K, Okada M, et
al. Soluble DNAM-1, as a predictive biomarker for acute
graft-versus-host disease. PloS one. 2016;11(6):e0154173.
24. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, et
al. Cotransplantation of mesenchymal stem cells might prevent death from
graft-versus-host disease (GVHD) without abrogating graft-versus-tumor
effects after HLA-mismatched allogeneic transplantation following
nonmyeloablative conditioning. Biology of blood and marrow
transplantation. 2010;16(6):838-47.
25. Kallekleiv M, Larun L, Bruserud Ø, Hatfield KJ. Co-transplantation
of multipotent mesenchymal stromal cells in allogeneic hematopoietic
stem cell transplantation: a systematic review and meta-analysis.
Cytotherapy. 2016;18(2):172-85.
26. Bacigalupo A. Mesenchymal stem cells and haematopoietic stem cell
transplantation. Best Practice & Research Clinical Haematology.
2004;17(3):387-99.
27. Tian Y, Deng Y, Huang Y, Wang Y. Bone marrow-derived mesenchymal
stem cells decrease acute graft-versus-host disease after allogeneic
hematopoietic stem cells transplantation. Immunological investigations.
2008;37(1):29-42.
28. Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, et al. Coinfusion of
mesenchymal stromal cells facilitates platelet recovery without
increasing leukemia recurrence in haploidentical hematopoietic stem cell
transplantation: a randomized, controlled clinical study. Stem cells and
development. 2011;20(10):1679-85.
29. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI,
et al. Rapid hematopoietic recovery after coinfusion of autologous-blood
stem cells and culture-expanded marrow mesenchymal stem cells in
advanced breast cancer patients receiving high-dose chemotherapy.
Journal of Clinical Oncology. 2000;18(2):307-.
30. Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L, et
al. Cotransplantation of human mesenchymal stem cells enhances human
myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Experimental
hematology. 2003;31(5):413-20.
31. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil
S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in
vitro and prolong skin graft survival in vivo. Experimental hematology.
2002;30(1):42-8.
32. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al.
Bone marrow mesenchymal stem cells inhibit the response of naive and
memory antigen-specific T cells to their cognate peptide. Blood.
2003;101(9):3722-9.
33. William TT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC.
Suppression of allogeneic T-cell proliferation by human marrow stromal
cells: implications in transplantation. Transplantation.
2003;75(3):389-97.
34. Frassoni F. Expanded mesenchymal stem cells (MSC), co-infused with
HLA identical hemopoietic stem cell transplants, reduce acute and
chronic graft-versus-host disease: a matched pair analysis. Bone Marrow
Transplant. 2002;29:S2.
35. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel
M, et al. Treatment of severe acute graft-versus-host disease with third
party haploidentical mesenchymal stem cells. The Lancet.
2004;363(9419):1439-41.
36. Zhao K, Liu Q. The clinical application of mesenchymal stromal cells
in hematopoietic stem cell transplantation. Journal of hematology &
oncology. 2016;9(1):46.
37. Nasef A. Role of Bone Marrow Derived Mesenchymal Stem Cells in
Management of Graft Versus Host Disease. Stem Cell Biology in Normal
Life and Diseases: IntechOpen; 2013.
38. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et
al. Cotransplantation of HLA-identical sibling culture-expanded
mesenchymal stem cells and hematopoietic stem cells in hematologic
malignancy patients. Biology of blood and marrow transplantation.
2005;11(5):389-98.
39. Ringdén O, Labopin M, Gorin N-C, Le Blanc K, Rocha V, Gluckman E, et
al. Treatment with granulocyte colony-stimulating factor after
allogeneic bone marrow transplantation for acute leukemia increases the
risk of graft-versus-host disease and death: a study from the Acute
Leukemia Working Party of the European Group for Blood and Marrow
Transplantation. Journal of clinical oncology. 2004;22(3):416-23.
40. Wu K-H, Tsai C, Wu H-P, Sieber M, Peng C-T, Chao Y-H. Human
application of ex vivo expanded umbilical cord-derived mesenchymal stem
cells: enhance hematopoiesis after cord blood transplantation. Cell
transplantation. 2013;22(11):2041-51.
41. Chao Y, Tsai C, Peng C, Wu H, Chan C, Weng T, et al.
Cotransplantation of umbilical cord MSCs to enhance engraftment of
hematopoietic stem cells in patients with severe aplastic anemia. Bone
marrow transplantation. 2011;46(10):1391-2.
42. Macmillan M, Blazar B, DeFor T, Wagner J. Transplantation of ex-vivo
culture-expanded parental haploidentical mesenchymal stem cells to
promote engraftment in pediatric recipients of unrelated donor umbilical
cord blood: results of a phase I–II clinical trial. Bone marrow
transplantation. 2009;43(6):447.
43. Kimura T, Asada R, Wang J, Kimura T, Morioka M, Matsui K, et al.
Identification of Long‐Term Repopulating Potential of Human Cord
Blood‐Derived CD34− flt3− Severe Combined Immunodeficiency‐Repopulating
Cells by Intra‐Bone Marrow Injection. Stem Cells. 2007;25(6):1348-55.
44. Pereira R, Halford K, O’hara M, Leeper D, Sokolov B, Pollard M, et
al. Cultured adherent cells from marrow can serve as long-lasting
precursor cells for bone, cartilage, and lung in irradiated mice.
Proceedings of the national academy of sciences. 1995;92(11):4857-61.
45. Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C,
Fouillard L, et al. Homing of in vitro expanded Stro-1-or Stro-1+ human
mesenchymal stem cells into the NOD/SCID mouse and their role in
supporting human CD34 cell engraftment. Blood. 2004;103(9):3313-9.
46. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, et
al. Mesenchymal stem cells are capable of homing to the bone marrow of
non-human primates following systemic infusion. Experimental hematology.
2001;29(2):244-55.
47. Horwitz E, Dominici M. How do mesenchymal stromal cells exert their
therapeutic benefit? Cytotherapy. 2008;10(8):771-4.
48. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein
LE. Human bone marrow stromal cells express a distinct set of
biologically functional chemokine receptors. Stem cells.
2006;24(4):1030-41.
49. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic
and functional comparison of cultures of marrow‐derived mesenchymal stem
cells (MSCs) and stromal cells. Journal of cellular physiology.
1998;176(1):57-66.
50. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J,
et al. Induction of the chemokine stromal-derived factor-1 following DNA
damage improves human stem cell function. The Journal of clinical
investigation. 2000;106(11):1331-9.
51. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B,
Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance
engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733.
52. Wang L, Zhang H, Guan L, Zhao S, Gu Z, Wei H, et al. Mesenchymal
stem cells provide prophylaxis against acute graft-versus-host disease
following allogeneic hematopoietic stem cell transplantation: A
meta-analysis of animal models. Oncotarget. 2016;7(38):61764.
53. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al.
Immunosuppressive effect of mesenchymal stem cells favors tumor growth
in allogeneic animals. Blood. 2003;102(10):3837-44.
54. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM,
et al. Cotransplantation of ex vivo–expanded mesenchymal stem cells
accelerates lymphocyte recovery and may reduce the risk of graft failure
in haploidentical hematopoietic stem-cell transplantation. Blood.
2007;110(7):2764-7.
55. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human
marrow-derived mesenchymal stem cells (MSCs) express hematopoietic
cytokines and support long-term hematopoiesis when differentiated toward
stromal and osteogenic lineages. Journal of hematotherapy & stem cell
research. 2000;9(6):841-8.
56. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier
N, et al. Evidence for a tumoral immune resistance mechanism based on
tryptophan degradation by indoleamine 2, 3-dioxygenase. Nature medicine.
2003;9(10):1269.
57. Olerup O, Zetterquist H. HLA‐DR typing by PCR amplification with
sequence‐specific primers (PCR‐SSP) in 2 hours: an alternative to
serological DR typing in clinical practice including donor‐recipient
matching in cadaveric transplantation. Tissue antigens.
1992;39(5):225-35.
58. Copelan E, Biggs J, Szer J, Thompson J, Crilley P, Brodsky I, et
al., editors. Allogeneic bone marrow transplantation for acute
myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma
following preparation with busulfan and cyclophosphamide (BuCy2).
Seminars in oncology; 1993.
59. Socié G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, et
al. Busulfan plus cyclophosphamide compared with total-body irradiation
plus cyclophosphamide before marrow transplantation for myeloid
leukemia: long-term follow-up of 4 randomized studies. Blood.
2001;98(13):3569-74.
60. Clift R, Buckner C, Thomas E, Bensinger W, Bowden R, Bryant E, et
al. Marrow transplantation for chronic myeloid leukemia: a randomized
study comparing cyclophosphamide and total body irradiation with
busulfan and cyclophosphamide. Blood. 1994;84(6):2036-43.
61. Storb R, Deeg HJ, Fisher L, Appelbaum F, Buckner CD, Bensinger W, et
al. Cyclosporine v methotrexate for graft-v-host disease prevention in
patients given marrow grafts for leukemia: long-term follow-up of three
controlled trials. Blood. 1988;71(2):293-8.
62. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J,
et al. 1994 Consensus conference on acute GVHD grading. Bone marrow
transplantation. 1995;15(6):825-8.
63. Atkinson K, Horowitz M, Gale R, Lee M, Rimm A, Bortin M. Consensus
among bone marrow transplanters for diagnosis, grading and treatment of
chronic graft-versus-host disease. Committee of the International Bone
Marrow Transplant Registry. Bone marrow transplantation.
1989;4(3):247-54.
64. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD,
Matteucci P, et al. Human bone marrow stromal cells suppress
T-lymphocyte proliferation induced by cellular or nonspecific mitogenic
stimuli. Blood. 2002;99(10):3838-43.
65. Troeger A, Meisel R, Moritz T, Dilloo D. Immunotherapy in allogeneic
hematopoietic stem cell transplantation–not just a case for effector
cells. Bone marrow transplantation. 2005;35(S1):S59.
66. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F.
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor
cells: impact on in vivo tumor growth. Leukemia. 2007;21(2):304-10.
67. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, et al. The
correlation between cotransplantation of mesenchymal stem cells and
higher recurrence rate in hematologic malignancy patients: outcome of a
pilot clinical study. Leukemia. 2008;22(3):593.
68. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL,
et al. Acute graft-versus-host disease biomarkers measured during
therapy can predict treatment outcomes: a Blood and Marrow Transplant
Clinical Trials Network study. Blood. 2012;119(16):3854-60.
69. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al.
ST2 as a marker for risk of therapy-resistant graft-versus-host disease
and death. New England Journal of Medicine. 2013;369(6):529-39.
70. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan
T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic
function of T lymphocytes. Immunity. 1996;4(6):573-81.
71. Nabekura T, Kanaya M, Shibuya A, Fu G, Gascoigne NR, Lanier LL.
Costimulatory molecule DNAM-1 is essential for optimal differentiation
of memory natural killer cells during mouse cytomegalovirus infection.
Immunity. 2014;40(2):225-34.
72. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B,
et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell
surface ligands for the human DNAM-1 (CD226) activating molecule.
Journal of Experimental Medicine. 2003;198(4):557-67.
73. Tahara-Hanaoka S, Shibuya K, Kai H, Miyamoto A, Morikawa Y, Ohkochi
N, et al. Tumor rejection by the poliovirus receptor family ligands of
the DNAM-1 (CD226) receptor. Blood. 2006;107(4):1491-6.
74. Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy
P, et al. An early-biomarker algorithm predicts lethal graft-versus-host
disease and survival. JCI insight. 2017;2(3).
75. Huang X, Liu D, Liu K, Xu L, Chen H, Han W, et al. Haploidentical
hematopoietic stem cell transplantation without in vitro T-cell
depletion for the treatment of hematological malignancies. Bone marrow
transplantation. 2006;38(4):291.